76 related articles for article (PubMed ID: 35045668)
21. The value of patient-reported outcomes to predict for symptom burden and health-related quality of life after chemoradiation for cervical cancer: A prospective study.
Andring LM; Corrigan KL; Reeve B; Meyer L; Wang XS; Smith G; Bailard N; Domingo M; Fellman B; Varkey J; Foster-Mills T; Lin L; Jhingran A; Colbert L; Eifel P; Klopp AH; Joyner M
Pract Radiat Oncol; 2024 May; ():. PubMed ID: 38825227
[TBL] [Abstract][Full Text] [Related]
22. Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities.
Coltro G; Loscocco GG; Vannucchi AM
Int Rev Cell Mol Biol; 2021; 365():1-69. PubMed ID: 34756241
[TBL] [Abstract][Full Text] [Related]
23. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
24. [Health-related quality of life and its associated variables in Chinese patients with Philadelphia-negative myeloproliferative neoplasms].
Bao M; Shi DY; Shi HX; Liu XL; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):985-992. PubMed ID: 35045668
[No Abstract] [Full Text] [Related]
25. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
26. Impact of Myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey.
Yu J; Parasuraman S; Paranagama D; Bai A; Naim A; Dubinski D; Mesa R
BMC Cancer; 2018 Apr; 18(1):420. PubMed ID: 29653557
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
Zhang MY; Bao M; Shi DY; Shi HX; Liu XL; Xu N; Duan MH; Zhuang JL; Du X; Qin L; Hui WH; Liang R; Wang MF; Chen Y; Li DY; Yang W; Tang GS; Zhang WH; Kuang X; Su W; Han YQ; Chen LM; Xu JH; Liu ZG; Huang J; Zhao CT; Tong HY; Hu JD; Chen CY; Chen XQ; Xiao ZJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2023 Mar; 44(3):193-201. PubMed ID: 37356980
[No Abstract] [Full Text] [Related]
28. The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.
Geyer HL; Andreasson B; Kosiorek HE; Dueck AC; Scherber RM; Martin KA; Butler KA; Harrison CN; Radia DH; Cervantes F; Kiladjian JJ; Reiter A; Birgegard G; Passamonti F; Senyak Z; Vannucchi AM; Paoli C; Xiao Z; Samuelsson J; Mesa RA
Cancer; 2016 Jun; 122(12):1888-96. PubMed ID: 27070130
[TBL] [Abstract][Full Text] [Related]
29. Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms.
Shi D; Shi H; Liu X; Duan M; Zhuang J; Du X; Qin L; Hui W; Liang R; Wang M; Chen Y; Li D; Yang W; Tang G; Zhang W; Kuang X; Su W; Han Y; Chen L; Xu J; Liu Z; Huang J; Zhao C; Tong H; Hu J; Chen C; Chen X; Xiao Z; Jiang Q
Leuk Lymphoma; 2021 Nov; 62(11):2703-2715. PubMed ID: 34098836
[TBL] [Abstract][Full Text] [Related]
30. [Analysis of the MPN Landmark survey for impact and perceptions of treatment goals among Chinese physicians and myeloproliferative neoplasm patients].
Xu ZF; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):570-575. PubMed ID: 32810964
[No Abstract] [Full Text] [Related]
31. [Patient-reported outcome and its application in hematological neoplasm].
Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):614-619. PubMed ID: 32397032
[No Abstract] [Full Text] [Related]
32. Financial Burdens of Cancer Treatment: A Systematic Review of Risk Factors and Outcomes.
Smith GL; Lopez-Olivo MA; Advani PG; Ning MS; Geng Y; Giordano SH; Volk RJ
J Natl Compr Canc Netw; 2019 Oct; 17(10):1184-1192. PubMed ID: 31590147
[TBL] [Abstract][Full Text] [Related]
33. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.
Mercieca-Bebber R; Costa DS; Norman R; Janda M; Smith DP; Grimison P; Gamper EM; King MT
Med J Aust; 2019 Jun; 210(11):499-506. PubMed ID: 31155722
[TBL] [Abstract][Full Text] [Related]
34. Ruxolitinib.
Ajayi S; Becker H; Reinhardt H; Engelhardt M; Zeiser R; von Bubnoff N; Wäsch R
Recent Results Cancer Res; 2018; 212():119-132. PubMed ID: 30069628
[TBL] [Abstract][Full Text] [Related]
35. Myeloproliferative Disorders.
Meier B; Burton JH
Hematol Oncol Clin North Am; 2017 Dec; 31(6):1029-1044. PubMed ID: 29078922
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
